Table 1 |.
Baseline characteristics of patients with SMM diagnosed in the study
| Variable | All patients with SMM (n = 193) | Patients with SMM in arm 3 (n = 112) |
|---|---|---|
| Median (range) age, years | 70 (44–92) | 70 (44–92) |
| Sex | ||
| Male | 116 (60) | 69 (62) |
| Female | 77 (40) | 43 (38) |
| Ethnicity | ||
| White | 173 (90) | 109 (97) |
| Asian | 1 (1) | 1 (1) |
| Unknown | 19 (10) | 2 (2) |
| Median (range) hemoglobin, g l−1 (range) | 138 (81–169) | 139 (81–169) |
| Median (range) creatinine, mmol l−1 (range) | 86 (42–577) | 86 (50–577) |
| Median (range) calcium, mmol l −1 (range) | 2.37 (2.15–2.81) | 2.36 (2.16–2.61) |
| Median (range) β−2 microglobulin, mg l−1 (range) | 7.2 (4.3–43.3) | 7.3 (4.8–26.5) |
| M protein (n) | 178 | 102 |
| Mean (range), g dl−1 | 0.62 (0.01–3.5) | 0.52 (0.01–2.1) |
| >1.0 g dl−1 | 37 (19) | 17 (15) |
| >2.0 g dl−1 | 4 (2) | 1 (1) |
| >3.0 g dl−1 | 1 (0.5) | 0 |
| FLC ratio | ||
| >1.65 or <0.26 | 122 (63) | 63 (56) |
| >20 or <0.05 | 28 (15) | 15 (13) |
| Isotype | ||
| IgG | 109 (56) | 61 (54) |
| Kappa | 64 | 30 |
| Lambda | 45 | 30 |
| IgA | 49 (25) | 32 (28) |
| Kappa | 27 | 18 |
| Lambda | 22 | 14 |
| IgM | 2 (1) | 0 |
| Biclonal | 5 (2) | 1 (1) |
| Light chain | 25 (13) | 18 (16) |
| Kappa | 17 | 10 |
| Lambda | 8 | 7 |
| Normal SPEP and FLC analysis | 3 (2) | 1 (1) |
| BMPCs | ||
| 11–20% | 141 (73) | 87 (78) |
| 21–30% | 33 (17) | 16 (14) |
| 31–40% | 11 (6) | 4 (4) |
| 41–50% | 8 (4) | 5 (4) |
| Immunoparesis | 46 (24) | 22 (20) |
| Risk score (2/20/20 risk model) | ||
| Low risk | 126 (65) | 76 (68) |
| Intermediate risk | 52 (27) | 30 (27) |
| High risk | 15 (8) | 6 (5) |
| Bone disease excluded with: | ||
| MR | 28 (14) | 12 (11) |
| CT | 143 (74) | 97 (87) |
| Skeletal survey | 13 (7) | 0 (0) |
| No imaging | 9 (5) | 2 (2) |
Data are shown as n (%) unless indicated otherwise.